Antenatal oral glucose tolerance test abnormalities in the prediction of future risk of postpartum diabetes in women with gestational diabetes: Results from the LIVING study.


Journal

Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326

Informations de publication

Date de publication:
May 2024
Historique:
revised: 27 02 2024
received: 31 10 2023
accepted: 19 03 2024
medline: 6 5 2024
pubmed: 6 5 2024
entrez: 6 5 2024
Statut: ppublish

Résumé

To explore associations between type and number of abnormal glucose values on antenatal oral glucose tolerance test (OGTT) with postpartum diabetes in South Asian women diagnosed with gestational diabetes (GDM) using International Association of the Diabetes and Pregnancy Study Groups criteria. This post-hoc evaluation of the Lifestyle Intervention IN Gestational Diabetes (LIVING) study, a randomized controlled trial, was conducted among women with GDM in the index pregnancy, across 19 centers in Bangladesh, India, and Sri Lanka. Postpartum diabetes (outcome) was defined on OGTT, using American Diabetes Association (ADA) criteria. We report data on 1468 women with GDM, aged 30.9 (5.0) years, and with median (interquartile range) follow-up period of 1.8 (1.4-2.4) years after childbirth following the index pregnancy. We found diabetes in 213 (14.5%) women with an incidence of 8.7 (7.6-10.0)/100 women-years. The lowest incidence rate was 3.8/100 women years, in those with an isolated fasting plasma glucose (FPG) abnormality, and highest was 19.0/100 women years in participants with three abnormal values. The adjusted hazard ratios for two and three abnormal values compared to one abnormal value were 1.73 (95% confidence interval [CI], 1.18-2.54; p = .005) and 3.56 (95% CI, 2.46-5.16; p < .001) respectively. The adjusted hazard ratio for the combined (combination of fasting and postglucose load) abnormalities was 2.61 (95% CI, 1.70-4.00; p < .001), compared to isolated abnormal FPG. Risk of diabetes varied significantly depending upon the type and number of abnormal values on antenatal OGTT. These data may inform future precision medicine approaches such as risk prediction models in identifying women at higher risk and may guide future targeted interventions.

Identifiants

pubmed: 38708437
doi: 10.1111/1753-0407.13559
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13559

Subventions

Organisme : Global Alliance for Chronic Disease
Organisme : National Health and Medical Research Council of Australia
ID : 1093171
Organisme : USV Pharmaceuticals Ltd
Organisme : Lupin Pharmaceuticals Ltd
Organisme : Global Alliance for Chronic Disease grants from the Indian Council of Medical Research

Informations de copyright

© 2024 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Références

Sweeting A, Wong J, Murphy HR, Ross GP. A clinical update on gestational diabetes mellitus. Endocr Rev. 2022;43:763‐793. doi:10.1210/endrev/bnac003
Pastore I, Chiefari E, Vero R, Brunetti A. Postpartum glucose intolerance: an updated overview. Endocrine. 2018;59:481‐494. doi:10.1007/s12020‐017‐1388‐0
ElSayed NA, Aleppo G, Aroda VR, et al. On behalf of the American Diabetes Association, 15. Management of Diabetes in pregnancy Standards of Care in Diabetes. Diabetes Care. 2023;46(supplement_1):S254‐S266.
Wang H, Li N, Chivese T, et al. IDF diabetes atlas committee Hyperglycaemia in pregnancy special interest group. IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in pregnancy study Group's criteria. Diabetes Res Clin Pract. 2022;183:109050. doi:10.1016/j.diabres.2021.109050
Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2020;63:1671‐1693. doi:10.1007/s00125‐020‐05181‐w
Nagraj S, Kennedy SH, Norton R, Jha V, Praveen D, Hinton L, Hirst JE. Cardiometabolic Risk Factors in Pregnancy and Implications for Long‐Term Health: Identifying the Research Priorities for Low‐Resource Settings. Front Cardiovasc Med. 2020;7:40. doi:10.3389/fcvm.2020.00040.
Moore LE, Voaklander B, Savu A, et al. Association between the antepartum oral glucose tolerance test and the risk of future diabetes mellitus among women with gestational diabetes: a systematic review and meta‐analysis. J Diabetes Complications. 2021;35:107804. doi:10.1016/j.jdiacomp.2020.107804
Hiersch L, Shah BR, Berger H, et al. For DOH‐NET (diabetes, obesity and hypertension in pregnancy research network) and SOON (southern Ontario obstetrical network) investigators. Oral glucose tolerance test results in pregnancy can Be used to individualize the risk of future maternal type 2 diabetes mellitus in women with gestational diabetes mellitus. Diabetes Care. 2021;44:1860‐1867. doi:10.2337/dc21‐0659
Dai F, Mani H, Nurul SR, Tan KH. Risk stratification of women with gestational diabetes mellitus using mutually exclusive categories based on the International Association of Diabetes and Pregnancy Study Groups criteria for the development of postpartum dysglycaemia: a retrospective cohort study. BMJ Open. 2022;12:e055458. doi:10.1136/bmjopen‐2021‐055458
Gupta Y, Kapoor D, Desai A, et al. Conversion of gestational diabetes mellitus to future type 2 diabetes mellitus and the predictive value of HbA1c in an Indian cohort. Diabet Med. 2017;34:37‐43. doi:10.1111/dme.13102
Goyal A, Gupta Y, Kalaivani M, et al. Long term (>1 year) postpartum glucose tolerance status among Indian women with history of gestational diabetes mellitus (GDM) diagnosed by IADPSG criteria. Diabetes Res Clin Pract. 2018;142:154‐161. doi:10.1016/j.diabres.2018.05.027
Gupta Y, Kapoor D, Lakshmi JK, et al. The incidence and risk factors of postpartum diabetes in women from Bangladesh, India and Sri Lanka (South Asia) with prior gestational diabetes mellitus: results from the LIVING study. Diabetes Res Clin Pract. 2023;204:110893. doi:10.1016/j.diabres.2023.110893
Tandon N, Gupta Y, Kapoor D, et al. Effects of a lifestyle intervention to prevent deterioration in glycemic status among south Asian women with recent gestational diabetes: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e220773. doi:10.1001/jamanetworkopen.2022.0773
ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: standards of Care in Diabetes‐2023. Diabetes Care. 2023;46(suppl_1):S19‐S40.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676‐682. doi:10.2337/dc09‐1848
Schemper M, Smith TL. A note on quantifying follow‐up in studies of failure time. Control Clin Trials. 1996;17:343‐346. doi:10.1016/0197‐2456(96)00075‐x
Bardugo A, Bendor CD, Rotem RS, et al. Glucose intolerance in pregnancy and risk of early‐onset type 2 diabetes: a population‐based cohort study. Lancet Diabetes Endocrinol. 2023;11(5):333‐344. doi:10.1016/S2213‐8587(23)00062‐1
Kotzaeridi G, Blätter J, Eppel D, et al. Characteristics of gestational diabetes subtypes classified by oral glucose tolerance test values. Eur J Clin Invest. 2021;51:e13628. doi:10.1111/eci.13628
Yeung RO, Retnakaran R, Savu A, Butalia S, Kaul P. Gestational diabetes: one size does not fit all‐an observational study of maternal and neonatal outcomes by maternal glucose profile. Diabet Med. 2024;41:e15205. doi:10.1111/dme.15205
Chatzakis C, Eleftheriades A, Demertzidou E, et al. Pregnancy outcomes in the different phenotypes of gestational diabetes mellitus based on the oral glucose tolerance test. A systematic review and meta‐analysis. Diabetes Res Clin Pract. 2023;204:110913. doi:10.1016/j.diabres.2023.110913

Auteurs

Yashdeep Gupta (Y)

Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.

Deksha Kapoor (D)

Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.

Josyula K Lakshmi (JK)

George Institute for Global Health, Hyderabad, India.
Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.

Devarsetty Praveen (D)

George Institute for Global Health, Hyderabad, India.
Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.

Joseph Alvin Santos (JA)

George Institute for Global Health, Sydney, New South Wales, Australia.

Laurent Billot (L)

Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
George Institute for Global Health, Sydney, New South Wales, Australia.

Aliya Naheed (A)

Initiative for Non Communicable Diseases, Nutrition Research Division, International Centre for Diarrhoeal Disease Research (ICDDR, B), Dhaka, Bangladesh.

H Asita de Silva (HA)

Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.

Ishita Gupta (I)

Centre for Chronic Disease Control, New Delhi, India.

Noshin Farzana (N)

Initiative for Non Communicable Diseases, Nutrition Research Division, International Centre for Diarrhoeal Disease Research (ICDDR, B), Dhaka, Bangladesh.

Renu John (R)

George Institute for Global Health, Hyderabad, India.

Saumiyah Ajanthan (S)

RemediumOne, Colombo, Sri Lanka.

Neerja Bhatla (N)

Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.

Ankush Desai (A)

Department of Endocrinology, Goa Medical College, Goa, India.

Arunasalam Pathmeswaran (A)

Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.

Dorairaj Prabhakaran (D)

Centre for Chronic Disease Control, New Delhi, India.
Public Health Foundation of India, New Delhi, India.
London School of Hygiene and Tropical Medicine, London, UK.

Helena Teede (H)

Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Sophia Zoungas (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Anushka Patel (A)

Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
George Institute for Global Health, Sydney, New South Wales, Australia.

Nikhil Tandon (N)

Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH